Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1020
AVAC Infographics for AIDS 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the...
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
Prevention Option:
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
Prevention Option:
HIV Prevention Pipeline: Products to Watch
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Prevention Option:
Long-Acting HIV Treatment Pipeline
AVAC has begun to track the research pipeline for long-acting HIV treatment (LA-ART). A rapidly expanding pipeline for LA-ART has the potential to introduce new regimens with dosing frequencies that range from weeks to months to, eventually, years. The benefits of LA-ART include reduced drug dosing, frequency, and number of drugs, with the potential for associated decreases in the cost of medications and the burden on health systems. New drug classes could close treatment gaps in children, adolescents, and those with high viremia, comorbidities and resistance.
Prevention Option:
HIV Cure Research Cohorts
HIV cure research depends on cohorts of people living with HIV who volunteer to participate in studies over many years. These cohorts help researchers understand how HIV persists in the body, identify factors that may influence the success of cure strategies and evaluate promising interventions. This infographic highlights major HIV cure research cohorts around the world, demonstrating the global collaboration and long-term investment required to advance HIV cure science.
Community First: Practical Strategies for Inclusive Implementation Science
Join The Choice Agenda and Hunter College’s Dr. Sarit Golub for a participatory discussion on implementation science – including opportunities, pitfalls and ways in which community leadership – beyond perfunctory...
The Future Won’t Build Itself: Sustaining the Movement CASPR Started
Join AVAC and partners as we launch the CASPR Impact Report, detailing the achievements of the Coalition to Accelerate & Support Prevention Research (CASPR) over the course of 8+ years. We will share these wins, discuss lessons for the field and...
CROI 2025 Cure Reflections Video Series
A PAVE (Pediatric Adolescent Virus Elimination) and REACH video series with HIV cure-related takeaways from CROI 2025.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
showing 1-10 of 1020